Literature DB >> 113817

The effect of propranolol treatment in shizophrenia on CSF amine metabolites and prolactin.

R H Belmaker, R P Ebstein, H Dasberg, A Levy, G Sedvall, H M Van Praag.   

Abstract

Recent reports have suggested that high doses of propranolol may be an effective treatment in schizophrenia. To determine whether such treatment has effects on cerebrospinal fluid (CSF) amine metabolites and prolactin similar to the effects of the neuroleptic drugs, we studied CSF from ten patients before and after propanolol therapy. The initial CSF sample was removed after a drug-free period and propranolol dosage was then increased over 1 week to 1000 mg daily in all ten patients. A second CSF sample was removed after 3 weeks of propranolol therapy. Propranolol levels and prolactin in CSF were measured by radioimmunoassay. Homovanillic acid, 5-hydroxyindoleacetic acid, and 3-methoxy-4-hydroxyphenylethylene glycol were measured by gas chromatography-mass spectrometry. Propranolol had no effect on the prolactin or amine metabolite concentrations. CSF propranolol levels averaged 40 ng/ml (range less than 1--78).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 113817     DOI: 10.1007/bf00433565

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists.

Authors:  M Weinstock; C Weiss; S Gitter
Journal:  Neuropharmacology       Date:  1977-04       Impact factor: 5.250

2.  Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.

Authors:  R M Post; F K Goodwin
Journal:  Science       Date:  1975-10-31       Impact factor: 47.728

3.  Prolactin responses to neuroleptics in normal and schizophrenic subjects.

Authors:  P H Gruen; E J Sachar; G Langer; N Altman; M Leifer; A Frantz; F S Halpern
Journal:  Arch Gen Psychiatry       Date:  1978-01

4.  Further studies with propranolol in psychotic patients. Relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxyphenylglycol excretion.

Authors:  A Atsmon; I Blum; M Steiner; A Latz; H Wijsenbeek
Journal:  Psychopharmacologia       Date:  1972

5.  Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion.

Authors:  G Alfredsson; F A Wiesel; P Skett
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

6.  Decrease in serum-prolactin after propranolol in schizophrenia.

Authors:  T Hanssen; T Heyden; I Sundberg; L Wetterberg; P Eneroth
Journal:  Lancet       Date:  1978-01-14       Impact factor: 79.321

Review 7.  Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs.

Authors:  D G Shand
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  Effects of high dose propranolol treatment on dopamine and norepinephrine metabolism in regions of rat brain.

Authors:  F A Wiesel
Journal:  Neurosci Lett       Date:  1976-03       Impact factor: 3.046

9.  Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method.

Authors:  B Sandgárde; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1976-07-28       Impact factor: 4.530

10.  Propranolol in the control of schizophrenic symptoms.

Authors:  N J Yorkston; S A Zaki; M K Malik; R C Morrison; C W Havard
Journal:  Br Med J       Date:  1974-12-14
View more
  3 in total

Review 1.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

2.  The effect of propranolol on CSF amine metabolites in psychiatric patients.

Authors:  D J King; S J Cooper; J Liddle
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

3.  Efficacy of propranolol on schizophrenic thought disorder.

Authors:  B B Sethi; S Dube
Journal:  Indian J Psychiatry       Date:  1981-10       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.